Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solid Biosciences Inc.

www.solidbio.com

Latest From Solid Biosciences Inc.

Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds

Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans. 

Financing Business Strategies

Adverse Event Concerns With Solid Biosciences' Candidate DMD Gene Therapy

The US FDA has for the second time placed a clinical hold on Solid Biosciences’ potential gene therapy for Duchenne muscular dystrophy, a move linked to a 70% decline in the company’s share price. The company had reported a serious adverse event in a patient treated with higher doses of the viral vector-delivered gene therapy.

 

Gene Therapy Clinical Trials

Made In China Gene Therapy A Father's Quest To Save Son With UltraRare Condition

Patient-driven drug development meets the old saying of "where there's a will, there's a way" in China, potentially the world's largest market for rare disease treatments.

Gene Therapy Innovation

Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label

Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Solid Ventures
  • Solid Biosciences LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Solid Biosciences Inc.
  • Senior Management
  • Ilan Ganot, CEO
    Jennifer Ziolkowski, CFO
    Carl Morris , PhD, CSO
    Joel Schneider, PhD, CTO, Head, Exploratory R&D
    Jorge A Quiroz, MD, CMO
    Alvaro Amorrortu, COO
  • Contact Info
  • Solid Biosciences Inc.
    Phone: (617) 337-4680
    161 First St.
    3rd Floor
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register